Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Fleming

Showing results (561-570 of 571) with videos related to

Pageof 58
Sort By:
JAMA Oncology|August 15, 2024
Breast Cancer Index in Premenopausal Women With Early-Stage Hormone Receptor-Positive Breast CancerRuth M O'Regan, Yi Zhang, Gini F Fleming, et al.
Cancer|September 23, 2025
Prognostic value of patient-reported depression in women with hormone-responsive early breast cancer in TEXT and SOFTKarin Ribi, Bernard F Cole, Gini F Fleming, et al.
The New England Journal of Medicine|December 16, 2014
Adjuvant ovarian suppression in premenopausal breast cancerPrudence A Francis, Meredith M Regan, Gini F Fleming, et al.
Breast Cancer Research and Treatment|May 8, 2020
Clinical evaluation of germline polymorphisms associated with capecitabine toxicity in breast cancer: TBCRC-015Peter H O'Donnell, Vassily Trubetskoy, Ashley Nurhussein-Patterson, et al.
The New England Journal of Medicine|June 3, 2014
Adjuvant exemestane with ovarian suppression in premenopausal breast cancerOlivia Pagani, Meredith M Regan, Barbara A Walley, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 28, 2023
Genomic characterisation of hormone receptor-positive breast cancer arising in very young womenS J Luen, G Viale, S Nik-Zainal, et al.
The New England Journal of Medicine|June 5, 2018
Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast CancerPrudence A Francis, Olivia Pagani, Gini F Fleming, et al.
Journal of the National Cancer Institute|June 19, 2013
Implementation of timeline reforms speeds initiation of National Cancer Institute-sponsored trialsJeffrey S Abrams, Margaret M Mooney, James A Zwiebel, et al.
The New England Journal of Medicine|September 29, 2019
Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian CancerRobert L Coleman, Gini F Fleming, Mark F Brady, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 2, 2026
Final outcomes of the SOFT and TEXT phase III trials in premenopausal hormone receptor-positive early breast cancerP A Francis, O Pagani, G F Fleming, et al.
Pageof 58

Showing results (561-570 of 571) with videos related to

Sort By:
Pageof 58
JAMA Oncology|August 15, 2024
Breast Cancer Index in Premenopausal Women With Early-Stage Hormone Receptor-Positive Breast CancerRuth M O'Regan, Yi Zhang, Gini F Fleming, et al.
Cancer|September 23, 2025
Prognostic value of patient-reported depression in women with hormone-responsive early breast cancer in TEXT and SOFTKarin Ribi, Bernard F Cole, Gini F Fleming, et al.
The New England Journal of Medicine|December 16, 2014
Adjuvant ovarian suppression in premenopausal breast cancerPrudence A Francis, Meredith M Regan, Gini F Fleming, et al.
Breast Cancer Research and Treatment|May 8, 2020
Clinical evaluation of germline polymorphisms associated with capecitabine toxicity in breast cancer: TBCRC-015Peter H O'Donnell, Vassily Trubetskoy, Ashley Nurhussein-Patterson, et al.
The New England Journal of Medicine|June 3, 2014
Adjuvant exemestane with ovarian suppression in premenopausal breast cancerOlivia Pagani, Meredith M Regan, Barbara A Walley, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 28, 2023
Genomic characterisation of hormone receptor-positive breast cancer arising in very young womenS J Luen, G Viale, S Nik-Zainal, et al.
The New England Journal of Medicine|June 5, 2018
Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast CancerPrudence A Francis, Olivia Pagani, Gini F Fleming, et al.
Journal of the National Cancer Institute|June 19, 2013
Implementation of timeline reforms speeds initiation of National Cancer Institute-sponsored trialsJeffrey S Abrams, Margaret M Mooney, James A Zwiebel, et al.
The New England Journal of Medicine|September 29, 2019
Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian CancerRobert L Coleman, Gini F Fleming, Mark F Brady, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 2, 2026
Final outcomes of the SOFT and TEXT phase III trials in premenopausal hormone receptor-positive early breast cancerP A Francis, O Pagani, G F Fleming, et al.
Pageof 58